ArticleACR open rheumatology2025
Gout Remission With Pegloticase-Induced Intensive Urate-Lowering Therapy: A Post Hoc Clinical Trial Analysis.
Article in ACR open rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03994731 (A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving KRYSTEXXA®), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving KRYSTEXXA® (Pegloticase) (MIRROR Randomized Controlled Trial [RCT])
Who cites it
1 citing paper in PubMed.
- Correction to "Gout Remission With Pegloticase-Induced Intensive Urate-Lowering Therapy: A Post Hoc Clinical Trial Analysis".ACR open rheumatology · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
Abstract
objectiveGout is a type of painful inflammatory arthritis that affects patient health and quality of life, making remission a crucial goal. The Gout Hyperuricemia and Crystal-Associated Disease Network (G-CAN) recently proposed a standard definition for gout remission. Using adapted criteria from de Lautour et al and recent G-CAN criteria, this post hoc analysis used existing data from the Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase (MIRROR) randomized controlled trial (NCT03994731) to determine potential gout remission rates in patients with pegloticase-induced intensive urate-lowering.
methodsBased on the adapted gout remission criteria from de Lautour et al, remission was defined as meeting all of the following six criteria: resolution of ≥1 tophus, serum urate (SU) level <6 mg/dL, no gout flares in the previous three months, pain score ≤1 (10-point scale), swollen joint count ≤1, and Physician Global Assessment of Gout score ≤1. An abbreviated three-criteria definition, modeled after the G-CAN definition, included gout flare, SU level, and tophus resolution.
resultsA total of 145 patients received ≥1 dose of pegloticase (pegloticase with methotrexate, n = 96; pegloticase with placebo, n = 49), with 90 and 74 patients remaining on treatment through weeks 24 and 52, respectively. At weeks 24 and 52, 13.3% of patients (12 of 90) and 43.2% of patients (32 of 74) achieved gout remission using the six-criteria definition, and 36.7% (33 of 90) and 70.3% of patients (52 of 74) achieved remission using the three-criteria definition.
conclusionUsing the study full and simplified definitions, nearly half to three-quarters of patients who remained on pegloticase for 52 weeks achieved gout remission. This novel analysis provides evidence that remission is possible in many patients with uncontrolled gout within one year of intensive, sustained urate-lowering.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.